| THIS WEEK’S LETTERS | |
|---|---|
| 2500 | Tumor Mutational Burden and Response Rate to PD-1 Inhibition |
| 2502 | Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes |
| 2503 | Nivolumab and Ipilimumab in Advanced Melanoma |
| 2504 | Hospital-Readmission Risk — Isolating Hospital Effects |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.